Abstract
Introduction/Aim While echocardiography plays an important role in the follow-up of patients with precapillary pulmonary hypertension (PH), several studies have identified World Health Oganization's functional class (WHO FC), 6-minute walk distance (6MWD) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as the strongest prognostic markers. We investigated the relationship between echocardiographic indices, functional status and NT-proBNP in patients with precapillary PH. Material and Methods A total of 23 patients were included in this retrospective study. Data were collected from routine risk assessments, including WHO FC, 6MWD, NT-proBNP, standard, strain and three-dimensional echocardiography. The echocardiographic data were analysed in terms of the patients' functional status as determined by WHO FC, 6MWD and NT-proBNP values. Results Patients in WHO FC III or IV had a shorter 6MWD [180 (interquartile range 85-240 m)] than patients in WHO FC I or II [409 (interquartile range 364-494 m), p=0.02)], while the difference in NT-proBNP was not statistically significant [FC I or II: 1297 (interquartile range 283-3196) versus FC III or IV: 343 (interquartile range 274-598) pg/ml, p=0.146]. There were inverse correlations between 6MWD and left and right ventricular longitudinal strain and a direct correlation between 6MWD and pulmonary acceleration time (r=0.73; p=0.001). NT-proBNP measurements were directly correlated with right heart dimensions and right ventricular strain and inversely correlated with pulmonary acceleration time (r=-0.70; p=0.004). Conclusion Standard and advanced echocardiographic indices of right ventricular structure, function and hemodynamics correlate with functional status and natriuretic peptide levels in a heterogeneous cohort of patients with precapillary PH and may be useful ancillary parameters in clinical practice.
Funder
Ministry of Education, Science and Technological Development of the Republic of Serbia
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference31 articles.
1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. PMID: 36017548 DOI: 10.1093/eurheartj/ehac237;
2. Kang M, Hart CM, Kempker JA, Veeraraghavan S, Trammell AW. Pulmonary hypertension mortality trends in United States 1999-2019. Ann Epidemiol. 2022;75:47-52. PMID: 36089225 DOI: 10.1016/j.annepidem.2022.09.001;
3. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017;50:1700740. PMID: 28775047 DOI: 10.1183/13993003.00740-2017;
4. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021;159(1):337-346. PMID: 32882243 DOI: 10.1016/j.chest.2020.08.2069;
5. Heresi GA, Dweik RA. Strengths and limitations of the six-minutewalk test: a model biomarker study in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(9):1122-4. PMID: 21531951 DOI: 10.1164/rccm.201012-2079ED;